COX-2–Selective NSAIDs: New and Improved?

Gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs (NSAIDs) is among the most common serious adverse drug events in the industrialized world. While cyclooxygenase-2 selective NSAIDs are effective in reducing the risk of symptomatic ulcers, careful postmarketing surveillance wi...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2000-09, Vol.284 (10), p.1297-1299
Main Authors: Lichtenstein, David R, Wolfe, M. Michael
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Celecoxib
Clinical trials
Cyclooxygenase 1
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors - adverse effects
Cyclooxygenase Inhibitors - therapeutic use
Gastric Mucosa - drug effects
Gastrointestinal Diseases - chemically induced
Humans
Isoenzymes - antagonists & inhibitors
Isoenzymes - pharmacology
Medical research
Membrane Proteins
Prostaglandin-Endoperoxide Synthases - pharmacology
Pyrazoles
Side effects
Sulfonamides - therapeutic use
Ulcers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs (NSAIDs) is among the most common serious adverse drug events in the industrialized world. While cyclooxygenase-2 selective NSAIDs are effective in reducing the risk of symptomatic ulcers, careful postmarketing surveillance will be required to determine their ultimate benefit and safety profile.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.284.10.1297